#1 - Eli Lilly and Co. (NYSE:LLY)
Eli Lilly and Co. (NYSE: LLY) - Eli Lilly is in that space where they have a lot of products in development – and many are showing enormous promise, but the stock has been struggling with declining revenues since a series of patents expired in 2011. One of their newer drugs, Solanezumab, an Alzheimer’s drug, failed to produce the expected results. However, the company is resting a lot of their hope on two of their newest cancer drugs Cyramza and Portrazza, which have been approved but are not yet at the point where they are generating tangible revenue for the company. The company also recently suffered a setback when a court ruled against their appeal of a $20 million patent lawsuit in which the company was accused of infringing on a German patent with its Cialis product.
From a technical standpoint, the stock has an earnings per share (EPS) of 2.27 which is down -37% for the year. This has brought their EPS forecast for next year to 3.87%. And the P/E multiple for the stock is around 43 which is above its multiple of 33 two years ago that was considered high at that time. However, the performance of the stock year-to-date is 30.01%. What seems to be of more concern for investors is that Eli Lilly seems to be accepting its underperformance instead of aggressively combating it.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More - Current Price
- $767.76
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 17 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $1,002.22 (30.5% Upside)
